Mikami, 6,000 patient HCQ late treatment study: 47% lower mortality [p<0.0001] https://c19p.org/mikami
copied to clipboard
Risk Factors for Mortality in Patients with COVID-19 in New York City
et al., J. Gen. Intern. Med., doi:10.1007/s11606-020-05983-z
HCQ decreases mortality, HR 0.53 (CI 0.41–0.67). IPTW adjustment does not significantly change HR 0.53 (0.41-0.68). Retrospective 6,000 patients in New York City.
|
risk of death, 47.0% lower, HR 0.53, p < 0.001, treatment 575 of 2,077 (27.7%), control 231 of 743 (31.1%), adjusted per study.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Mikami et al., 6/30/2020, retrospective, USA, North America, peer-reviewed, 7 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.